Reviewing Eloxx Pharmaceuticals (ELOX) and Its Competitors

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Eloxx Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Earnings & Valuation

This table compares Eloxx Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.86
Eloxx Pharmaceuticals Competitors	$3.50 billion	$3.13 billion	547.43

Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Eloxx Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7612	13663	25494	1003	2.42

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, suggesting a potential upside of 129.13%. As a group, “Pharmaceuticals” companies have a potential upside of 27.31%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than its peers.

Institutional and Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of -3.17, indicating that their average stock price is 417% less volatile than the S&P 500.

Profitability

This table compares Eloxx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,319.38%	-223.56%	-16.98%

Summary

Eloxx Pharmaceuticals beats its peers on 7 of the 13 factors compared.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.